Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 1, 2001, Pages 61-69

  Zannikos, P N ^a   Rohatagi, S ^a   Jensen, B K ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; FATTY ACID; PLACEBO;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERANCE; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; HUMAN; LIPOLYSIS; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034749394     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122009845     Document Type: Article

References (34)

1. A comparison between the adenosine receptors mediating adenylate cyclase inhibition and cardiac depression in the guinea pig heart
2. 1 receptors
3. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology
4. Adenosine receptors: New opportunities for future drugs
5. The pharmacology of adenosine
6. 2-receptor agonists on myocardial reperfusion injury
7. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no-reflow phenomenon
8. 2 receptor against AMP 579 in a porcine model of myocardial infarction
9. Effect of adenosine adenosine analogues and drugs inhibiting adenosine inactivation on lipolysis in rat fat cells
10. Suppression of non-esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236
11. Effects of an N6-disubstituted adenosine derivative (B.M. 11.189) on fat cell metabolism
12. Free fatty acid metabolism during myocardial ischemia and reperfusion
13. Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction
14. Enzymatic determination of serum-free fatty acids: A calorimetric method
15. An information criterion (AIC)
16. Pharmacodynamic model of tolerance: Application to nicotine
17. Pharmacokineticpharmacodynamic modeling of caffeine: Tolerance to pressor effects
18. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
19. Subclasses of external adenosine receptors
20. Adenosine analogs inhibit adenylate cyclase by a GTP-dependent process: Basis for actions of adenosine and methylxanthines on cyclic AMP production and lipolysis
21. Growth hormone, cortisol, and glucagon concentration during plasma free fatty acid depression: Different effects of nicotinic acid and an adenosine derivative (BM11.189)
22. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine
23. 6-(p-sulphonphenyl)adenosine in rats
24. 1 receptor agonists in rats: Prediction of tissue-dependent efficacy in vivo
25. 1-receptor agonists
26. Desensitization of adenosine receptor-mediated inhibition of lipolysis
27. Cellular tolerance to adenosine receptor-mediated inhibition of lipolysis: Altered adenosine 3',5'-monophosphate metabolism and protein kinase activation
28. 1 adenosine receptor agonist: Alterations in the quantity of G(sα) and G(iα) are not associated with changes in their mRNAs
29. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist
30. Drug tolerance and physical dependence
31. Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications
32. Potential of adenosine receptor agonists for the prevention and treatment of coronary artery disease and acute myocardial infarction